TY - JOUR
T1 - Retinal Diseases
T2 - The Next Frontier in Pharmacodelivery
AU - Ben-Arzi, Assaf
AU - Ehrlich, Rita
AU - Neumann, Ron
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/5
Y1 - 2022/5
N2 - The future continuous growth of the global older population augments the burden of retinal diseases worldwide. Retinal characteristics isolating and protecting the sensitive neuro-retina from the rest of the ocular tissues challenge drug delivery and promote research and development toward new horizons. In this review, we wish to describe the unmet medical needs, discuss the novel modes of delivery, and disclose to the reader a spectrum of older-to-novel drug delivery technologies, innovations, and the frontier of pharmacodelivery to the retina. Treating the main retinal diseases in the everlasting war against blindness and its associated morbidity has been growing steadily over the last two decades. Implants, new angiogenesis inhibitor agents, micro-and nano-carriers, and the anchored port delivery system are becoming new tools in this war. The revolution and evolution of new delivery methods might be just a few steps ahead, yet its assimilation in our daily clinical work may take time, due to medical, economical, and regulatory elements that need to be met in order to allow successful development and market utilization of new technologies. Therefore, further work is warranted, as detailed in this Pharmaceutics Special Issue.
AB - The future continuous growth of the global older population augments the burden of retinal diseases worldwide. Retinal characteristics isolating and protecting the sensitive neuro-retina from the rest of the ocular tissues challenge drug delivery and promote research and development toward new horizons. In this review, we wish to describe the unmet medical needs, discuss the novel modes of delivery, and disclose to the reader a spectrum of older-to-novel drug delivery technologies, innovations, and the frontier of pharmacodelivery to the retina. Treating the main retinal diseases in the everlasting war against blindness and its associated morbidity has been growing steadily over the last two decades. Implants, new angiogenesis inhibitor agents, micro-and nano-carriers, and the anchored port delivery system are becoming new tools in this war. The revolution and evolution of new delivery methods might be just a few steps ahead, yet its assimilation in our daily clinical work may take time, due to medical, economical, and regulatory elements that need to be met in order to allow successful development and market utilization of new technologies. Therefore, further work is warranted, as detailed in this Pharmaceutics Special Issue.
KW - Port delivery systems
KW - age-related macular degeneration (AMD)
KW - anti-vascular endothelial growth factor (VEGF)
KW - designed ankyrin repeat protein (DARP)
KW - diabetic retinopathy
KW - global aging
KW - hydrogel
KW - implant
KW - liposome
KW - micro-and nano-carriers
KW - micro-and nanoparticles
KW - pharmacodelivery and drug delivery
UR - http://www.scopus.com/inward/record.url?scp=85129435174&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics14050904
DO - 10.3390/pharmaceutics14050904
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 35631490
AN - SCOPUS:85129435174
SN - 1999-4923
VL - 14
JO - Pharmaceutics
JF - Pharmaceutics
IS - 5
M1 - 904
ER -